Close

Research Insight

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced final results from a retrospective study

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced final results from a retrospective study including more than 260,000 patients that showed the risk of acute pancreatitis among initiators of BYETTA(R) (exenatide) injection was not increased compared to initiators...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read